Skip to main content
NCBI home page
American Journal of Human Genetics logoLink to American Journal of Human Genetics
. 1985 May;37(3):499–510.

Gaucher disease types 1, 2, and 3: differential mutations of the acid beta-glucosidase active site identified with conduritol B epoxide derivatives and sphingosine.

G A Grabowski, T Dinur, K M Osiecki, J R Kruse, G Legler, S Gatt
PMCID: PMC1684582  PMID: 4003396

Abstract

To elucidate the genetic heterogeneity in Gaucher disease, the residual beta-glucosidase in cultured fibroblasts from affected patients with each of the major phenotypes was investigated in vitro and/or in viable cells by inhibitor studies using the covalent catalytic site inhibitors, conduritol B epoxide or its bromo derivative, and the reversible cationic inhibitor, sphingosine. These studies delineated three distinct groups (designated A, B, and C) of residual activities with characteristic responses to these inhibitors. Group A residual enzymes had normal I50 values (i.e., the concentration of inhibitor that results in 50% inhibition) for the inhibitors and normal or nearly normal t1/2 values for conduritol B epoxide. All neuronopathic (types 2 and 3) and most non-Jewish nonneuronopathic (type 1) patients had group A residual activities and, thus, could not be distinguished by these inhibitor studies. Group B residual enzymes had about four- to fivefold increased I50 values for the inhibitors and similarly increased t1/2 values for conduritol B epoxide. All Ashkenazi Jewish type 1 and only two non-Jewish type 1 patients had group B residual activities. The differences in I50 values between groups A and B also were confirmed by determining the uninhibited enzyme activity after culturing the cells in the presence of bromo-conduritol B epoxide. Group C residual activity had intermediate I50 values for the inhibitors and represented a single Afrikaner type 1 patient: this patient was a genetic compound for the group A (type 2) and group B (type 1) mutations. These inhibition studies indicated that: Gaucher disease type 1 is biochemically heterogeneous, neuronopathic and non-Jewish nonneuronopathic phenotypes cannot be reliably distinguished by these inhibitor studies, and the Ashkenazi Jewish form of Gaucher disease type 1 results from a unique mutation in a specific active site domain of acid beta-glucosidase that leads to a defective enzyme with a decreased Vmax.

Full text

PDF
499

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. BRADY R. O., KANFER J. N., SHAPIRO D. METABOLISM OF GLUCOCEREBROSIDES. II. EVIDENCE OF AN ENZYMATIC DEFICIENCY IN GAUCHER'S DISEASE. Biochem Biophys Res Commun. 1965 Jan 18;18:221–225. doi: 10.1016/0006-291x(65)90743-6. [DOI] [PubMed] [Google Scholar]
  2. BRINN L., GLABMAN S. Gaucher's disease without splenomegaly. Oldest patient on record, with review. N Y State J Med. 1962 Jul 15;62:2346–2354. [PubMed] [Google Scholar]
  3. Basu A., Glew R. H., Daniels L. B., Clark L. S. Activators of spleen glucocerebrosidase from controls and patients with various forms of Gaucher's disease. J Biol Chem. 1984 Feb 10;259(3):1714–1719. [PubMed] [Google Scholar]
  4. Dinur T., Grabowski G. A., Desnick R. J., Gatt S. Synthesis of a fluorescent derivative of glucosyl ceramide for the sensitive determination of glucocerebrosidase activity. Anal Biochem. 1984 Jan;136(1):223–234. doi: 10.1016/0003-2697(84)90329-4. [DOI] [PubMed] [Google Scholar]
  5. Dreborg S., Erikson A., Hagberg B. Gaucher disease--Norrbottnian type. I. General clinical description. Eur J Pediatr. 1980 Mar;133(2):107–118. doi: 10.1007/BF00441578. [DOI] [PubMed] [Google Scholar]
  6. GAVER R. C., SWEELEY C. C. METHODS FOR METHANOLYSIS OF SPHINGOLIPIDS AND DIRECT DETERMINATION OF LONG-CHAIN BASES BY GAS CHROMATOGRAPHY. J Am Oil Chem Soc. 1965 Apr;42:294–298. doi: 10.1007/BF02540132. [DOI] [PubMed] [Google Scholar]
  7. Gatt S., Dinur T., Desnick R. J. Studies on human acid beta-glucosidase and the nature of the molecular defect in type 1 Ashkenazi Gaucher disease. Prog Clin Biol Res. 1982;95:315–331. [PubMed] [Google Scholar]
  8. Ginns E. I., Brady R. O., Pirruccello S., Moore C., Sorrell S., Furbish F. S., Murray G. J., Tager J., Barranger J. A. Mutations of glucocerebrosidase: discrimination of neurologic and non-neurologic phenotypes of Gaucher disease. Proc Natl Acad Sci U S A. 1982 Sep;79(18):5607–5610. doi: 10.1073/pnas.79.18.5607. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Ginns E. I., Choudary P. V., Martin B. M., Winfield S., Stubblefield B., Mayor J., Merkle-Lehman D., Murray G. J., Bowers L. A., Barranger J. A. Isolation of cDNA clones for human beta-glucocerebrosidase using the lambda gt11 expression system. Biochem Biophys Res Commun. 1984 Sep 17;123(2):574–580. doi: 10.1016/0006-291x(84)90268-7. [DOI] [PubMed] [Google Scholar]
  10. Ginns E. I., Tegelaers F. P., Barneveld R., Galjaard H., Reuser A. J., Brady R. O., Tager J. M., Barranger J. A. Determination of Gaucher's disease phenotypes with monoclonal antibody. Clin Chim Acta. 1983 Jul 15;131(3):283–287. doi: 10.1016/0009-8981(83)90097-9. [DOI] [PubMed] [Google Scholar]
  11. Grabowski G. A., Gatt S., Kruse J., Desnick R. J. Human lysosomal beta-glucosidase: kinetic characterization of the catalytic, aglycon, and hydrophobic binding sites. Arch Biochem Biophys. 1984 May 15;231(1):144–157. doi: 10.1016/0003-9861(84)90371-0. [DOI] [PubMed] [Google Scholar]
  12. Hodson P., Goldblatt J., Beighton P. Non-neuropathic Gaucher disease presenting in infancy. Arch Dis Child. 1979 Sep;54(9):707–709. doi: 10.1136/adc.54.9.707. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Legler G. Glucosidases. Methods Enzymol. 1977;46:368–381. doi: 10.1016/s0076-6879(77)46044-0. [DOI] [PubMed] [Google Scholar]
  14. MALONEY A. F., CUMINGS J. N. A case of juvenile Gaucher's disease with intraneuronal lipid storage. J Neurol Neurosurg Psychiatry. 1960 Aug;23:207–213. doi: 10.1136/jnnp.23.3.207. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. MEDOFF A. S., BAYRD E. D. Gaucher's disease in 29 cases: hematologic complications and effect of splenectomy. Ann Intern Med. 1954 Mar;40(3):481–492. doi: 10.7326/0003-4819-40-3-481. [DOI] [PubMed] [Google Scholar]
  16. Mumford R. A., Raghavan S. S., Kanfer J. N. Hydrolytic and transglucolytic activities of a partially purified calf brain beta-glucosidase. J Neurochem. 1976 Oct;27(4):943–948. doi: 10.1111/j.1471-4159.1976.tb05159.x. [DOI] [PubMed] [Google Scholar]
  17. Pentchev P. G., Neumeyer B., Svennerholm L., Groth C. G., Brady R. O. Immunological and catalytic quantitation of splenic glucocerebrosidase from the three clinical forms of Gaucher disease. Am J Hum Genet. 1983 Jul;35(4):621–628. [PMC free article] [PubMed] [Google Scholar]
  18. Raghavan S. S., Mumford R. A., Kanfer J. N. Deficiency of glucosylsphingosine: beta-glucosidase in Gaucher disease. Biochem Biophys Res Commun. 1973 Sep 5;54(1):256–263. doi: 10.1016/0006-291x(73)90916-9. [DOI] [PubMed] [Google Scholar]
  19. Rose J. S., Grabowski G. A., Barnett S. H., Desnick R. J. Accelerated skeletal deterioration after splenectomy in Gaucher type 1 disease. AJR Am J Roentgenol. 1982 Dec;139(6):1202–1204. doi: 10.2214/ajr.139.6.1202. [DOI] [PubMed] [Google Scholar]
  20. Turner B. M., Hirschhorn K. Properties of beta-glucosidase in cultured skin fibroblasts from controls and patients with Gaucher disease. Am J Hum Genet. 1978 Jul;30(4):346–358. [PMC free article] [PubMed] [Google Scholar]

Articles from American Journal of Human Genetics are provided here courtesy of American Society of Human Genetics

RESOURCES